Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating the efficacy and safety of baricitinib for systemic sclerosis. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Tongji Hospital | Conditions: Systemic Sclerosis | Phase 4 | Status: ACTIVE_NOT_RECRUITING